See the DrugPatentWatch profile for Diroximel
What is diroximel fumarate, and what does “Biogen” have to do with it?
Diroximel fumarate is an oral medicine for people with relapsing forms of multiple sclerosis (MS). It is marketed in the US under the brand name Vumerity. It is made by Biogen, the company associated with the drug’s development and commercialization.
What condition is diroximel fumarate used to treat?
Diroximel fumarate is used to treat relapsing forms of multiple sclerosis, including relapsing-remitting MS. It helps reduce the frequency of relapses.
How does it compare with Tecfidera (dimethyl fumarate)?
Diroximel fumarate and Tecfidera (dimethyl fumarate) are closely related fumarate-based MS therapies. Diroximel fumarate was developed as an alternative formulation intended to improve gastrointestinal tolerability for some patients while providing the same underlying fumarate mechanism.
What are common side effects people look for?
Commonly reported side effects for fumarate-based MS treatments include flushing and gastrointestinal symptoms (such as nausea, diarrhea, and abdominal discomfort). Patients may also be monitored for blood changes as part of routine safety follow-up.
How is it taken?
Diroximel fumarate is taken by mouth on a daily schedule, using a starter approach to reduce early side effects, then increasing to the maintenance dose as directed by a clinician.
Is Biogen the only company that makes it?
In practice, the brand is Biogen’s (Vumerity). Over time, other manufacturers may be able to enter the market with generic or follow-on versions depending on patent and regulatory timelines, but Biogen is the company tied to the original branded product.
Sources
- https://www.vumerity.com/ (official Vumerity site)
- https://www.biogen.com/ (Biogen company site)
- https://reference.medscape.com/drug/vumerity-diroximel-fumarate-1000084 (drug overview including indication and dosing)